Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 5, 2003, Pages 397-405

  Tayrouz, Yorki ^a   Ding, Reinhard ^a   Burhenne, Jürgen ^a   Riedel, Klaus Dieter ^a   Weiss, Johanna ^a   Hoppe Tichy, Torsten ^a   Haefeli, Walter Emil ^a   Mikus, Gerd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; DIGOXIN; GELATIN; GLYCOPROTEIN P;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGOXIN BLOOD LEVEL; DISSOLUTION; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DISPOSITION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TRANSPORT; ELECTROCARDIOGRAM; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET;

ADULT; BIOLOGICAL AVAILABILITY; CAPSULES; CARDIOTONIC AGENTS; CROSS-OVER STUDIES; DIGOXIN; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; EXCIPIENTS; FEMALE; GELATIN; HEART RATE; HUMANS; MALE; POLYETHYLENE GLYCOLS; SOLUBILITY;

EID: 0037799910     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00059-6     Document Type: Article

References (34)

1. Magnani B, Malini PL. Cardiac glycosides. Drug interactions of clinical significance. Drug Saf 1995;12:97-109.
2. Hinderling PH, Hartmann D. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther Drug Monit 1991;13:381-401.
3. de Lannoy IA, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992;189:551-7.
4. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-98.
5. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998;64:123-8.
6. Woodland C, Ito S, Koren G. A model for the prediction of digoxin-drug interactions at the renal tubular cell level. Ther Drug Monit 1998;20:134-8.
7. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338-45.
8. Kovarik JM, Rigaudy L, Guerret M, Gerbeau C, Rost KL. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol Ther 1999;66:391-400.
9. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001;70:311-6.
10. Cavet ME, West M, Simmons NL. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 1996;118:1389-96.
11. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104:147-53.
12. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 2000;68:6-12.
13. Stephens RH, O'Neill CA, Warhurst A, Carlson GL, Rowland M, Warhurst G. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 2001;296:584-91.
14. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, et al. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 2001;296:723-35.
15. Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, Williams B, et al. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 1990;50:4199-203.
16. Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, et al. Reversal of multidrug resistance by surfactants. Br J Cancer 1992;66:62-8.
17. Cornaire G, Woodley JF, Saivin S, Legendre JY, Decourt S, Cloarec A, et al. Effect of polyoxyl 35 castor oil and polysorbate 80 on the intestinal absorption of digoxin in vitro. Arzneimittelforschung 2000;50:576-9.
18. Webster LK, Cosson EJ, Stokes KH, Millward MJ. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 1996;73:522-4.
19. Martin-Facklam M, Burhenne J, Ding R, Fricker R, Mikus G, Walter-Sack I, et al. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid Cremophor EL. Br J Clin Pharmacol 2002;53:576-81.
20. BASF. Technisches Merkblatt: Cremophor RH40. Burgbernheim (Germany): BASF; 1999.
21. Wandel C, Kim RB, Wood AJJ, Stein CM. Inactive ingredients may alter bioavailability of drugs through effects on P-glycoprotein (Pgp) and CYP3A. Clin Pharmacol Ther 2001;69:P71 [abstract].
22. Nauck M, Stein U, von Karger S, Marz W, Wieland H. Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridization probes. Clin Chem 2000;46:1995-7.
23. Breitkreutz J. Leakage of enteric (Eudragit L)-coated dosage forms in simulated gastric juice in the presence of poly(ethylene glycol). J Control Release 2000;67:79-88.
24. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996;17:354-81.
25. Aszalos A, Thompson K, Yin JJ, Ross DD. Combinations of P-glycoprotein blockers, verapamil, PSC833, and Cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp). Anticancer Res 1999;19:1053-64.
26. Gibaldi M, Feldman S. Mechanisms of surfactant effects on drug absorption. J Pharm Sci 1970;59:579-89.
27. Necheles H, Sporn J. Effect of detergents on gastric motility. Am J Gastroenterol 1966;46:481-3.
28. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 1981;305:789-94.
29. Ragueneau I, Poirier JM, Radembino N, Sao AB, Funck-Brentano C, Jaillon P. Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. Br J Clin Pharmacol 1999;48:453-6.
30. Bardelmeijer HA, Ouwehand M, Malingre MM, Schellens JH, Beijnen JH, van Tellingen O. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. Cancer Chemother Pharmacol 2002;49:119-25.
31. Malingre MM, Schellens JH, van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, et al. The cosolvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br J Cancer 2001;85:1472-7.
32. Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DK, van Asperen J, et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol 1996;119:1038-44.
33. Pauli-Magnus C, Feiner J, Brett C, Lin ET, Kroetz DL. No effect of MDR1 C3435T polymorphism on disposition and CNS effects of loperamide. Clin Pharmacol Ther 2002;71:P72 [abstract].
34. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003;43:285-307.